ClinicalTrials.gg
SuspendedNCT03288389Updated Apr 20, 2020

Membrane Lipid Replacement in Fibromyalgia

An interventional study of NTFactor Lipids® and Placebo in Fibromyalgia, sponsored by Institute for Molecular Medicine. Suspended at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Institute for Molecular Medicine · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
until further notice due to COVID-19 pandemic.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Planned enrollment
175th of 320
60 · median 72
Started
2017
with 12 others
No phase
167 of 369
34 open now
Registered
234th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 175th largest by planned enrollment of the 320 interventional ones that give a count, is one of 13 that started in 2017, is one of 167 with no phase, and was the 234th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the clinical effectiveness of an all-natural, patented wafer with active ingredients that are FDA approved as Generally Recognized as Safe (GRAS) Reference: US Federal Drug Administration (1970) Scientific Literature Reviews GRAS Report, PB-241 970. Active Ingredients: Lecithins. .In this study the investigators will evaluate the efficacy of this dietary product called NTFactor Lipids® made by Nutritional Therapeutics, Inc. of New York on pain, fatigue and gastrointestinal symptoms as well as quality of life indicators in adult male and female participants with fibromyalgia. The addition of NTFactor Lipids to the diet is expected to improve cellular energy function, decrease fatigue and pain and lower the severity of other symptoms and improve quality of life indicators in Fibromyalgia. This study will be a randomized, placebo-controlled, cross-over study.

Read the detailed description

Adult male and female volunteers (n=60, aged 18-64) with a diagnosis of Fibromyalgia will be recruited by referral, newspapers, flyers, radio and internet ads, and asked to complete an Informed Consent document and take an on-line, validated, Combined Fibromyalgia Symptom Questionnaire or Survey Form. Potentially eligible participants (Since there are approx. twice as many female as male patients with this diagnosis, the investigators anticipate that more female than male participants will be recruited) will have the Fibromyalgia diagnosis confirmed using the American College of Rheumatology criteria. If participants have not done so, participants will be asked to provide 10 cc of blood for a Chem 20 analysis. Participants that meet the inclusion criteria will be randomized into placebo (42 days) or supplement arms (4 g NTFactor Lipids® per day for 42 days) by a Research Nurse/Associate, and blinded to the Principal Investigators and Participants for this cross-over trial. After the first arm is completed, participants will return for a clinic visit and enter the second arm for 42 days after a 2-week wash-out period. Once the data has been collected online (at Day 0 before starting supplement/placebo and on Days 1, 2, 3, 7, 14, 21, 30 and 42 for each arm), data will be placed into spread sheets, unblinded and analyzed by an independent statistical unit at the University of California, Irvine, School of Medicine. Principal objectives will be to assess various categories of pain, fatigue, GI symptoms and QOL and compare these outcomes in this study among supplement and placebo arms for each participant over time and combined for all participants. Statistical significance of any differences will be determined by t-test and other methods. Regression analysis of the data will be used to assess fidelity of the data and reliability of outcomes, and R2 values will be calculated for combined data.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Membrane Lipid Replacement
  • NTFactor Lipids
  • Fibromyalgia
  • Pain
  • Fatigue
  • Gastrointestinal symptoms
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. You are an adult male or female (aged 18-70).
  2. You have Fibromyalgia or a related clinical condition.
  3. You are mobile during the day.
  4. You are willing to sign an document.
  5. You are willing to have 10 cc (two teaspoons) of blood drawn for analysis.
  6. You are willing to take part in a clinical study that will last 14 weeks.
  7. You have internet access and an email address.

Exclusion criteria

Exclusion Criteria:

  1. You are not an adult.
  2. You do not have Fibromyalgia or a related clinical condition.
  3. You are not mobile, spending more than 10 hours per day in bed.
  4. You are not willing and able to sign an document.
  5. You are not able to be present at a test location or have a blood draw of 10 cc (2 teaspoons) for blood analysis.
  6. You have unusually high or low values on your blood chemistry screen.
  7. You are pregnant
  8. You have been declared mentally incompetent by a qualified health care professional.
  9. You have a positive diagnosis of cancer, , hepatitis and other major illnesses, such as severe hypertension, neurodegenerative or disease.
  10. You on immune suppressing drugs or medications.
  11. You are legally barred from signing and informed consent document.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.

    Dietary Supplement: Placebo

  • Active comparator
    NTFactor Lipids®

    Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.

    Dietary Supplement: NTFactor Lipids®

Interventions

  • Dietary supplementNTFactor Lipids®

    Membrane Lipid Replacement with NTFactor Lipids wafers

    Also known as: Patented Energy wafers

  • Dietary supplementPlacebo

    Placebo wafers

06

What researchers measure

Primary outcomes

  1. Fatigue as assessed by validated survey form

    Fatigue elements and overall fatigue will be self reported ten times in each six week phase

    Time frame: through study completion at 14 weeks

  2. Pain as assessed by validated survey form

    Pain elements will be self reported ten times in each six week phase

    Time frame: through study completion at 14 weeks

  3. Gastrointestinal symptoms as assessed by validated survey form

    Gastrointestinal symptoms will be self reported ten times in each six week phase

    Time frame: through study completion at 14 weeks

Secondary outcomes

  1. Quality of Life as assessed by validated survey form

    QOL elements will be self reported ten times in each six week phase

    Time frame: through study completion at 14 weeks

07

Study locations

3 sites
  • Priority Health & Wellness
    Pearland, Texas 77581, United States
  • Office of Dr. Paul Breeding
    San Antonio, Texas 78209, United States
  • Blue Hole Wellness
    Wimberley, Texas 78676, United States
08

References and documents

Publications

  • Nicolson GL, Ash ME. Membrane Lipid Replacement for chronic illnesses, aging and cancer using oral glycerolphospholipid formulations with fructooligosaccharides to restore phospholipid function in cellular membranes, organelles, cells and tissues. Biochim Biophys Acta Biomembr. 2017 Sep;1859(9 Pt B):1704-1724. doi: 10.1016/j.bbamem.2017.04.013. Epub 2017 Apr 18. PubMed 28432031 ↗
  • Nicolson GL, Rosenblatt S, de Mattos GF, Settineri R, Breeding PC, Ellithorpe RR, Ash ME. Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer. Discoveries (Craiova). 2016 Feb 18;4(1):e54. doi: 10.15190/d.2016.1. PubMed 32309576 ↗
  • Nicolson GL. Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements. Integr Med (Encinitas). 2014 Aug;13(4):35-43. PubMed 26770107 ↗
  • Nicolson GL. Membrane Lipid Replacement: clinical studies using a natural medicine approach to restoring membrane function and improving health. International Journal of Clinical Medicine 7: 133-143, 2016;

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2017 (actual). Primary completion is estimated for May 2022, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2017
First posted
Sep 20, 2017
StartActual
May 1, 2017
Primary completionEst.
May 1, 2022
CompletionEst.
Jun 1, 2023
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03288389
Lead sponsor
Institute for Molecular Medicine
Responsible party
Garth Nicolson, PhD, MD (H) (President & Chief Scientific Officer, Institute for Molecular Medicine) — Principal investigator
First posted
Sep 20, 2017
Start date
May 1, 2017
Primary completion
May 1, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Apr 20, 2020

Study contacts

Nancy C Russell, DrPH
study director · Independent Research Coordinator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion